Brief: Allena Pharma Achieves Alignment With FDA On Phase 3 Program For Reloxaliase

Allena Pharmaceuticals

02/01/2019 13:13

Jan 2 (Reuters) - Allena Pharmaceuticals Inc  ALNA.O :
    * ALLENA PHARMACEUTICALS ACHIEVES ALIGNMENT WITH FDA ON
PHASE 3
PROGRAM AND ACCELERATED APPROVAL PATHWAY FOR RELOXALIASE IN
ENTERIC HYPEROXALURIA
    * ALLENA PHARMACEUTICALS INC - URIROX-2, SECOND PIVOTAL
PHASE 3
TRIAL, INITIATED IN Q4 OF 2018
    * ALLENA PHARMACEUTICALS INC - URIROX-1, FIRST PIVOTAL PHASE
3
TRIAL, ENROLLING; TOPLINE DATA EXPECTED IN SECOND HALF OF 2019
    * ALLENA PHARMACEUTICALS INC - PRIMARY EFFICACY ENDPOINT OF
CHANGE
IN URINARY OXALATE EXCRETION AT FOUR WEEKS

Source text for Eikon:  ID:nGNX3gn71 
Further company coverage:  ALNA.O 

 (Reuters.Briefs@thomsonreuters.com)